OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
Elisabetta Signoriello, Giacomo Lus, Simona Bonavita, et al.
Multiple Sclerosis Journal (2021) Vol. 28, Iss. 1, pp. 93-101
Closed Access | Times Cited: 15
Elisabetta Signoriello, Giacomo Lus, Simona Bonavita, et al.
Multiple Sclerosis Journal (2021) Vol. 28, Iss. 1, pp. 93-101
Closed Access | Times Cited: 15
Showing 15 citing articles:
Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review
Xavier Montalbán, Paul M. Matthews, Alex Simpson, et al.
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 3, pp. 302-311
Open Access | Times Cited: 24
Xavier Montalbán, Paul M. Matthews, Alex Simpson, et al.
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 3, pp. 302-311
Open Access | Times Cited: 24
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
Maria Cellerino, Giacomo Boffa, Caterina Lapucci, et al.
Neurotherapeutics (2021) Vol. 18, Iss. 4, pp. 2579-2588
Open Access | Times Cited: 27
Maria Cellerino, Giacomo Boffa, Caterina Lapucci, et al.
Neurotherapeutics (2021) Vol. 18, Iss. 4, pp. 2579-2588
Open Access | Times Cited: 27
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab
Doriana Landi, Alfonso Grimaldi, Francesca Bovis, et al.
Neurology Neuroimmunology & Neuroinflammation (2022) Vol. 9, Iss. 3
Open Access | Times Cited: 15
Doriana Landi, Alfonso Grimaldi, Francesca Bovis, et al.
Neurology Neuroimmunology & Neuroinflammation (2022) Vol. 9, Iss. 3
Open Access | Times Cited: 15
Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis
Gro Owren Nygaard, Hilde Marie Torgauten, Lars Skattebøl, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 62, pp. 103812-103812
Closed Access | Times Cited: 13
Gro Owren Nygaard, Hilde Marie Torgauten, Lars Skattebøl, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 62, pp. 103812-103812
Closed Access | Times Cited: 13
Prediction of multiple sclerosis outcomes when switching to ocrelizumab
Michael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Multiple Sclerosis Journal (2021) Vol. 28, Iss. 6, pp. 958-969
Open Access | Times Cited: 13
Michael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Multiple Sclerosis Journal (2021) Vol. 28, Iss. 6, pp. 958-969
Open Access | Times Cited: 13
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
Steffen Pfeuffer, Leoni Rolfes, Jens Ingwersen, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 3
Open Access | Times Cited: 5
Steffen Pfeuffer, Leoni Rolfes, Jens Ingwersen, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 3
Open Access | Times Cited: 5
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis
Lisa Graille-Avy, Clémence Boutière, Camille Rigollet, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 3
Open Access | Times Cited: 1
Lisa Graille-Avy, Clémence Boutière, Camille Rigollet, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 3
Open Access | Times Cited: 1
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod—potentials and risks of subsequent highly active agents
Melanie Korsen, Steffen Pfeuffer, Leoni Rolfes, et al.
Journal of Neurology (2022) Vol. 269, Iss. 5, pp. 2806-2818
Open Access | Times Cited: 7
Melanie Korsen, Steffen Pfeuffer, Leoni Rolfes, et al.
Journal of Neurology (2022) Vol. 269, Iss. 5, pp. 2806-2818
Open Access | Times Cited: 7
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
Elisabetta Signoriello, Giacomo Lus, Francesco Saccà, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1768-1768
Open Access | Times Cited: 3
Elisabetta Signoriello, Giacomo Lus, Francesco Saccà, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1768-1768
Open Access | Times Cited: 3
Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study
Emanuele D’Amico, Aurora Zanghì, Roberta Fantozzi, et al.
Current Neuropharmacology (2023) Vol. 21, Iss. 12, pp. 2563-2566
Open Access | Times Cited: 3
Emanuele D’Amico, Aurora Zanghì, Roberta Fantozzi, et al.
Current Neuropharmacology (2023) Vol. 21, Iss. 12, pp. 2563-2566
Open Access | Times Cited: 3
Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
Pilar Santiago-Setien, Cristina Barquín-Rego, Paula Hernández-Martínez, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Pilar Santiago-Setien, Cristina Barquín-Rego, Paula Hernández-Martínez, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Prediction of relapse activity when switching to cladribine for multiple sclerosis
Michael Zhong, Anneke van der Walt, Mastura Monif, et al.
Multiple Sclerosis Journal (2022) Vol. 29, Iss. 1, pp. 119-129
Closed Access | Times Cited: 2
Michael Zhong, Anneke van der Walt, Mastura Monif, et al.
Multiple Sclerosis Journal (2022) Vol. 29, Iss. 1, pp. 119-129
Closed Access | Times Cited: 2
Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis
Ali Ussama Fakih, Mohammad Ali Sahraian, Sepideh Paybast, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 71, pp. 104564-104564
Closed Access
Ali Ussama Fakih, Mohammad Ali Sahraian, Sepideh Paybast, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 71, pp. 104564-104564
Closed Access
A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivation
Salimata Gassama, A Garmendia, François‐Xavier Lejeune, et al.
Revue Neurologique (2023) Vol. 179, Iss. 9, pp. 1035-1038
Closed Access
Salimata Gassama, A Garmendia, François‐Xavier Lejeune, et al.
Revue Neurologique (2023) Vol. 179, Iss. 9, pp. 1035-1038
Closed Access
Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice
Aigli G. Vakrakou, Maria-Evgenia Brinia, Anastasia Alexaki, et al.
International Immunopharmacology (2023) Vol. 125, pp. 111192-111192
Closed Access
Aigli G. Vakrakou, Maria-Evgenia Brinia, Anastasia Alexaki, et al.
International Immunopharmacology (2023) Vol. 125, pp. 111192-111192
Closed Access
